All studies
CompletedPhase IIInterventional

Study of etoposide carboplatin chemotherapy in combination with pembrolizumab and lenvatinib therapy in advanced high-grade neuroendocrine tumours

Neuroendocrine tumours are rare cancers that start in specialised cells that release hormones. Fast-growing, advanced neuroendocrine tumours are usually treated with standard chemotherapy drugs called carboplatin and etoposide. While these work well initially, the cancer often stops responding over time. This trial, called the PELICAN study, is testing whether adding two newer medicines can help. In the first phase, patients receive standard chemotherapy alongside pembrolizumab, an immunotherapy drug that helps the immune system spot and attack cancer cells. Patients who complete this stage then start maintenance treatment. This involves taking pembrolizumab along with lenvatinib, a daily tablet that blocks the blood vessels tumours need to grow. The main aim is to find out if this combination is safe and helps people live longer without their cancer growing.

At a glance

Status
Completed
Phase
Phase II
Sponsor
Imperial College London
Enrolment target
20
Start
19 Sep 2023
Estimated completion
21 Oct 2025

What is this study about?

Neuroendocrine tumours (NETs) develop from cells that share traits with both nerve cells and hormone-producing cells. When these tumours are 'high-grade', it means the cells are growing and dividing quickly. The usual first choice of treatment is a combination of two chemotherapy drugs: carboplatin and etoposide. Although this chemotherapy often shrinks the tumours at first, the cancer frequently finds ways to resist the medicine.

To overcome this resistance, researchers at Imperial College London are testing a two-stage approach using modern cancer therapies alongside chemotherapy. The first stage adds an immunotherapy drug called pembrolizumab to the standard chemotherapy. Pembrolizumab works by releasing a 'brake' on your immune system, allowing your own white blood cells to recognise and attack cancer cells.

After four rounds of this combined treatment, patients who are doing well move into the second stage, known as maintenance. During maintenance, patients continue receiving pembrolizumab and start taking a targeted drug called lenvatinib as a daily tablet. Lenvatinib works by cutting off the tumour's blood supply, starving cancer cells of oxygen and nutrients to stop them growing back.

By combining these different treatments, researchers hope to give patients longer-lasting control over their cancer. This phase II study is taking place across four hospital sites in the UK to check both how safe the combination is and how effectively it controls the disease.

Key takeaways

  • A UK trial testing a new combination of chemotherapy, immunotherapy, and targeted tablets.
  • Aimed at adults with newly diagnosed, advanced, fast-growing neuroendocrine tumours.
  • Treatment is split into two stages: an initial 12-week stage followed by up to two years of maintenance.
  • Regular CT scans and blood tests are used to track your health and tumour response.
  • Participation is voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is for adults aged 18 and over who have been diagnosed with an advanced, fast-growing (high-grade) neuroendocrine carcinoma. To take part, you must have measurable tumour areas that doctors can track on scans, and you must not have had full-body drug treatments, like chemotherapy, for advanced disease before.

Your general health also matters. Doctors will check your 'performance status', which simply means looking at how well you can carry out your daily activities. Your kidneys, liver, and bone marrow need to be working reasonably well so that your body can handle the trial medicines safely.

Because these medicines can harm an unborn baby and may affect fertility, you cannot take part if you are pregnant or breastfeeding. Women who could become pregnant will need a negative pregnancy test before starting and must agree to use reliable contraception throughout the study and for four months afterwards. Both men and women should discuss fertility with their care team.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with advanced, high-grade neuroendocrine carcinoma.
  3. I have not yet received chemotherapy or other full-body treatment for advanced cancer.
  4. I am well enough to carry out light daily activities.
  5. I am willing to use reliable contraception during and after the study if applicable.
Answer every question to see your result.

What does participation involve?

If you join the trial, your treatment is split into two parts: induction and maintenance. Induction lasts around 12 weeks and involves four three-week cycles. During each cycle, you will visit the hospital to receive carboplatin, etoposide, and pembrolizumab through a drip directly into a vein.

After completing the four induction cycles, you move onto maintenance therapy. In this phase, you visit the clinic every three weeks for a pembrolizumab drip and take a lenvatinib tablet by mouth once a day at home. You can stay on maintenance for up to two years, as long as your cancer does not grow and you do not experience severe side effects.

To check how well the treatment is working, you will have a CT scan three weeks after finishing induction, and then every nine weeks during maintenance. You will also have regular blood tests, blood pressure checks, and clinic appointments to monitor your general wellbeing.

Potential risks and benefits

Taking part may help keep your cancer under control for longer, but there is no guarantee you will personally benefit. The study will also provide valuable information to help future patients. All cancer treatments carry risks of side effects. Pembrolizumab can cause joint pain, skin rashes, fever, or back pain, and can occasionally cause the immune system to attack healthy organs. Lenvatinib frequently causes high blood pressure, loose stools (diarrhoea), swelling, sore skin on the hands and feet, and reduced blood platelets. Chemotherapy can also lower blood counts, leading to fatigue and a higher risk of infections. Your team will monitor you closely and can adjust doses or give medicines to help manage side effects. Joining is entirely your choice, and you can leave the study at any time without your regular NHS care being affected.

Locations (3)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Imperial College Healthcare NHS Trust
    City only
    London, England
  • The Christie NHS Foundation Trust
    City only
    Manchester, England
  • Royal Free London NHS Foundation Trust
    City only
    London, England

Common questions

What is the difference between chemotherapy and immunotherapy?

Chemotherapy works by directly attacking and killing rapidly dividing cells, including cancer cells. Immunotherapy does not kill cancer directly; instead, it trains your body's own immune system to spot and destroy the cancer.

Do I have to stay in hospital for the treatment?

Most trial treatments are given in the outpatient day clinic, meaning you can usually go home the same day. The lenvatinib tablets are taken at home.

What happens if I experience severe side effects?

Your safety comes first. If side effects become difficult to manage, your doctors can temporarily pause your treatment, lower your dose, or prescribe other medicines to relieve your symptoms.

Will taking part affect my ability to have children?

Lenvatinib can affect fertility in both men and women, and the effects may be long-lasting. If having children in the future is important to you, speak with your care team about options such as freezing eggs or sperm before starting.

What happens if my cancer gets worse during the trial?

Doctors will monitor your progress closely with regular CT scans. If scans show the cancer is growing, the trial treatment will stop, and your doctor will discuss alternative treatment options with you.

How to find out more

Maria Martinez

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.